长 COVID 患者的前炎症细胞因子图谱在不同变异纪元之间存在差异。

IF 3 Q1 PRIMARY HEALTH CARE
Ravindra Ganesh, Siddhant Yadav, Ryan T Hurt, Michael R Mueller, Christopher A Aakre, Elizabeth A Gilman, Stephanie L Grach, Joshua Overgaard, Melissa R Snyder, Nerissa M Collins, Ivana T Croghan, Andrew D Badley, Raymund R Razonable, Bradley R Salonen
{"title":"长 COVID 患者的前炎症细胞因子图谱在不同变异纪元之间存在差异。","authors":"Ravindra Ganesh, Siddhant Yadav, Ryan T Hurt, Michael R Mueller, Christopher A Aakre, Elizabeth A Gilman, Stephanie L Grach, Joshua Overgaard, Melissa R Snyder, Nerissa M Collins, Ivana T Croghan, Andrew D Badley, Raymund R Razonable, Bradley R Salonen","doi":"10.1177/21501319241254751","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Over 30% of patients with COVID-19 have persistent symptoms that last beyond 30 days and referred to as Long COVID. Long COVID has been associated with a persistent elevation in peripheral cytokines including interleukin-6, interleukin-1β, and tumor necrosis factor-α. This study reports cytokine profiles of patients in our clinic across SARS-COV-2 variant epochs.</p><p><strong>Methods: </strong>The clinical cytokine panel was analyzed in patients with Long COVID during periods that were stratified according to variant epoch. The 4 variant epochs were defined as: (1) wild-type through alpha, (2) alpha/beta/gamma, (3) delta, and (4) omicron variants.</p><p><strong>Results: </strong>A total of 390 patients had the clinical cytokine panel performed; the median age was 48 years (IQR 38-59) and 62% were female. Distribution by variant was wild-type and alpha, 50% (n = 196); alpha/beta/gamma, 7.9% (n = 31); delta, 18% (n = 72); and omicron, 23% (n = 91). Time to cytokine panel testing was significantly longer for the earlier epochs. Tumor necrosis factor-α (<i>P</i> < .001) and interleukin 1β (<i>P</i> < .001) were significantly more elevated in the earlier epochs (median of 558 days in wild-type through Alpha epoch vs 263 days in omicron epoch, <i>P</i> < .001)). Nucleocapsid antibodies were consistently detected across epochs.</p><p><strong>Discussion: </strong>When stratified by variant epoch, patients with early epoch Long COVID had persistently elevated peripheral pro-inflammatory cytokine levels when compared to later epoch Long COVID. Patients with Long COVID have similar clusters of symptoms across epochs, suggesting that the underlying pathology is independent of the peripheral cytokine signature.</p>","PeriodicalId":46723,"journal":{"name":"Journal of Primary Care and Community Health","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11138192/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pro Inflammatory Cytokines Profiles of Patients With Long COVID Differ Between Variant Epochs.\",\"authors\":\"Ravindra Ganesh, Siddhant Yadav, Ryan T Hurt, Michael R Mueller, Christopher A Aakre, Elizabeth A Gilman, Stephanie L Grach, Joshua Overgaard, Melissa R Snyder, Nerissa M Collins, Ivana T Croghan, Andrew D Badley, Raymund R Razonable, Bradley R Salonen\",\"doi\":\"10.1177/21501319241254751\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Over 30% of patients with COVID-19 have persistent symptoms that last beyond 30 days and referred to as Long COVID. Long COVID has been associated with a persistent elevation in peripheral cytokines including interleukin-6, interleukin-1β, and tumor necrosis factor-α. This study reports cytokine profiles of patients in our clinic across SARS-COV-2 variant epochs.</p><p><strong>Methods: </strong>The clinical cytokine panel was analyzed in patients with Long COVID during periods that were stratified according to variant epoch. The 4 variant epochs were defined as: (1) wild-type through alpha, (2) alpha/beta/gamma, (3) delta, and (4) omicron variants.</p><p><strong>Results: </strong>A total of 390 patients had the clinical cytokine panel performed; the median age was 48 years (IQR 38-59) and 62% were female. Distribution by variant was wild-type and alpha, 50% (n = 196); alpha/beta/gamma, 7.9% (n = 31); delta, 18% (n = 72); and omicron, 23% (n = 91). Time to cytokine panel testing was significantly longer for the earlier epochs. Tumor necrosis factor-α (<i>P</i> < .001) and interleukin 1β (<i>P</i> < .001) were significantly more elevated in the earlier epochs (median of 558 days in wild-type through Alpha epoch vs 263 days in omicron epoch, <i>P</i> < .001)). Nucleocapsid antibodies were consistently detected across epochs.</p><p><strong>Discussion: </strong>When stratified by variant epoch, patients with early epoch Long COVID had persistently elevated peripheral pro-inflammatory cytokine levels when compared to later epoch Long COVID. Patients with Long COVID have similar clusters of symptoms across epochs, suggesting that the underlying pathology is independent of the peripheral cytokine signature.</p>\",\"PeriodicalId\":46723,\"journal\":{\"name\":\"Journal of Primary Care and Community Health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11138192/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Primary Care and Community Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/21501319241254751\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PRIMARY HEALTH CARE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Primary Care and Community Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/21501319241254751","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PRIMARY HEALTH CARE","Score":null,"Total":0}
引用次数: 0

摘要

背景:超过 30% 的 COVID-19 患者症状持续超过 30 天,被称为长 COVID。长COVID与外周细胞因子(包括白细胞介素-6、白细胞介素-1β和肿瘤坏死因子-α)的持续升高有关。本研究报告了本诊所患者在不同 SARS-COV-2 变异纪元的细胞因子概况:根据变异纪元分层,对长 COVID 患者的临床细胞因子谱进行了分析。4 个变异纪元被定义为(1)α野生型,(2)α/β/γ,(3)δ和(4)Ω变异型:共有 390 名患者接受了临床细胞因子检测;中位年龄为 48 岁(IQR 38-59),62% 为女性。变异体的分布情况为:野生型和α型,50%(n = 196);α/β/γ型,7.9%(n = 31);δ型,18%(n = 72);Ω型,23%(n = 91)。较早时间段的细胞因子检测时间明显较长。肿瘤坏死因子-α(P P P 讨论:按变异纪元分层时,早期纪元长COVID患者的外周促炎细胞因子水平持续升高,晚期纪元长COVID患者的外周促炎细胞因子水平持续升高。长COVID患者在不同变异纪元具有相似的症状群,这表明潜在的病理变化与外周细胞因子特征无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pro Inflammatory Cytokines Profiles of Patients With Long COVID Differ Between Variant Epochs.

Background: Over 30% of patients with COVID-19 have persistent symptoms that last beyond 30 days and referred to as Long COVID. Long COVID has been associated with a persistent elevation in peripheral cytokines including interleukin-6, interleukin-1β, and tumor necrosis factor-α. This study reports cytokine profiles of patients in our clinic across SARS-COV-2 variant epochs.

Methods: The clinical cytokine panel was analyzed in patients with Long COVID during periods that were stratified according to variant epoch. The 4 variant epochs were defined as: (1) wild-type through alpha, (2) alpha/beta/gamma, (3) delta, and (4) omicron variants.

Results: A total of 390 patients had the clinical cytokine panel performed; the median age was 48 years (IQR 38-59) and 62% were female. Distribution by variant was wild-type and alpha, 50% (n = 196); alpha/beta/gamma, 7.9% (n = 31); delta, 18% (n = 72); and omicron, 23% (n = 91). Time to cytokine panel testing was significantly longer for the earlier epochs. Tumor necrosis factor-α (P < .001) and interleukin 1β (P < .001) were significantly more elevated in the earlier epochs (median of 558 days in wild-type through Alpha epoch vs 263 days in omicron epoch, P < .001)). Nucleocapsid antibodies were consistently detected across epochs.

Discussion: When stratified by variant epoch, patients with early epoch Long COVID had persistently elevated peripheral pro-inflammatory cytokine levels when compared to later epoch Long COVID. Patients with Long COVID have similar clusters of symptoms across epochs, suggesting that the underlying pathology is independent of the peripheral cytokine signature.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.80
自引率
2.80%
发文量
183
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信